Retention in care of HIV-infected pregnant and lactating women starting ART under Option B+ in rural Mozambique

Tropical Medicine and International Health

Volumn 21, Issue 8, 2016, Pages 1003-1012

  Llenas García, Jara ^a   Wikman Jorgensen, Philip ^a   Hobbins, Michael ^a   Mussa, Manuel Aly ^b   Ehmer, Jochen ^a   Keiser, Olivia ^c   Mbofana, Francisco ^d   Wandeler, Gilles ^c,e  

^a SolidarMed ^*  (Switzerland)

^b Health Provincial Directorate   (Mozambique)

^c UNIVERSITY OF BERN   (Switzerland)

^d National Health Institute   (Mozambique)

^e UNIVERSITY OF BERN   (Switzerland)

Author keywords

HIV; Option B+; prevention of mother to child transmission; retention in care; rural Southern Africa; women's health

Indexed keywords

CHILDBEARING; DISEASE CONTROL; HEALTH CARE; HEALTH RISK; HORIZONTAL TRANSMISSION; HUMAN IMMUNODEFICIENCY VIRUS; LACTATION; NATIONAL STRATEGY; PREGNANCY; RISK FACTOR; RURAL AREA; WOMENS HEALTH;

CHILD; CONTROLLED STUDY; COUNSELING; DIAGNOSIS; FEMALE; FOLLOW UP; HEALTH CENTER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; MAJOR CLINICAL STUDY; MALE; MODEL; MOZAMBIQUE; PREGNANCY; RISK FACTOR; WOMEN'S HEALTH;

MOZAMBIQUE;

EID: 84981263619     PISSN: 13602276     EISSN: 13653156     Source Type: Journal    
DOI: 10.1111/tmi.12728     Document Type: Article

References (44)

1. UNAIDS. Mozambique. Epidemiological Fact Sheet, 2013.
2. UNICEF. Preventing mother-to-child transmission (PMTCT) of HIV. Eastern and Southern Africa.
3. Shapiro RL, Hughes MD, Ogwu A et al. Antiretroviral regimens in pregnancy and breast-feeding in Botswana. N Engl J Med 2010: 362: 2282–2294.
4. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med 2015: 373: 795–807.
5. WHO. Use of Antiretroviral Drugs for Treating Pregnant Women and Preventing HIV Infection in Infants. WHO Library Cataloging-in-Publication Data; April 2012.
6. Schouten EJ, Jahn A, Midiani D et al. Prevention of mother-to-child transmission of HIV and the health-related Millennium Development Goals: time for a public health approach. Lancet 2011: 378: 282–284.
7. Schouten EJ, Jahn A, Chimbwandira F, Harries AD, Van Damme W. Is Option B+ the best choice? Lancet 2013: 381: 1272–1273.
8. O'Brien L, Shaffer N, Sangrujee N, Abimbola TO. The incremental cost of switching from Option B to Option B+ for the prevention of mother-to-child transmission of HIV. Bull World Health Organ 2014: 92: 162–170.
9. Ishikawa N, Shimbo T, Miyano S et al. Health outcomes and cost impact of the new WHO 2013 guidelines on prevention of mother-to-child transmission of HIV in Zambia. PLoS ONE 2014: 9: e90991.
10. Gopalappa C, Stover J, Shaffer N, Mahy M. The costs and benefits of Option B+ for the prevention of mother-to-child transmission of HIV. AIDS 2014: 28 (Suppl 1): S5–S14.
11. Fasawe O, Avila C, Shaffer N et al. Cost-effectiveness analysis of Option B+ for HIV prevention and treatment of mothers and children in Malawi. PLoS ONE 2013: 8: e57778.
12. Ciaranello AL, Perez F, Engelsmann B et al. Cost-effectiveness of World Health Organization 2010 guidelines for prevention of mother-to-child HIV transmission in Zimbabwe. Clin Infect Dis 2013: 56: 430–446.
13. Impact of an innovative approach to prevent mother-to-child transmission of HIV–Malawi, July 2011-September 2012. MMWR Morb Mortal Wkly Rep 2013;62:148–151.
14. Koole O, Houben RM, Mzembe T et al. Improved retention of patients starting antiretroviral treatment in Karonga District, northern Malawi, 2005–2012. J Acquir Immune Defic Syndr 2014: 67: e27–e33.
15. Tenthani L, Haas AD, Tweya H et al. Retention in care under universal antiretroviral therapy for HIV-infected pregnant and breastfeeding women (‘Option B+’) in Malawi. AIDS 2014: 28: 589–598.
16. Wandeler G, Keiser O, Pfeiffer K et al. Outcomes of antiretroviral treatment programs in rural Southern Africa. J Acquir Immune Defic Syndr 2012: 59: e9–e16.
17. Bhardwaj S, Carter B, Aarons GA, Chi BH. Implementation Research for the Prevention of Mother-to-Child HIV Transmission in Sub-Saharan Africa: Existing Evidence, Current Gaps, and New Opportunities. Curr HIV/AIDS Rep 2015: 12: 246–255.
18. Health Mo. National Survey of Prevalence, Behavioral Risks, and Information About HIV and AIDS in Mozambique. Ministry of Health: Maputo, 2009.
19. INE. Estatísticas do Distrito de Ancuabe. Instituto Nacional de Estatística: Maputo, Moçambique, 2012; 1–32.
20. Abubacar A, Macurire Z, David L et al. Relatorio da supervisão específica dos programas de ITS/HIV/SIDA, PTV e TB. Pemba, Mozambique, 2012.
21. Bastos R, Manuel R, Osman N et al. Guia de Tratamento Antiretroviral e Infecções Oportunistas no Adulto, Adolescente e Grávida 2010/2011. Ministério da Saúde. Direcção Naional de Assistência Médica: Maputo, 2011.
22. Egger M, Ekouevi DK, Williams C et al. Cohort Profile: the international epidemiological databases to evaluate AIDS (IeDEA) in sub-Saharan Africa. Int J Epidemiol 2012: 41: 1256–1264.
23. Team RC. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing: Vienna, Austria, 2014.
24. Gray B. cmprsk: Subdistribution Analysis of Competing risks. R package version 2. 2–7, 2014.
25. Chi BH, Yiannoutsos CT, Westfall AO et al. Universal definition of loss to follow-up in HIV treatment programs: a statistical analysis of 111 facilities in Africa, Asia, and Latin America. PLoS Med 2011: 8: e1001111.
26. Johnson LF, Estill J, Keiser O et al. Do increasing rates of loss to follow-up in antiretroviral treatment programs imply deteriorating patient retention? Am J Epidemiol 2014: 180: 1208–1212.
27. Scrucca L, Santucci A, Aversa F. Competing risk analysis using R: an easy guide for clinicians. Bone Marrow Transplant 2007: 40: 381–387.
28. Scrucca L, Santucci A, Aversa F. Regression modeling of competing risk using R: an in depth guide for clinicians. Bone Marrow Transplant 2010: 45: 1388–1395.
29. Fine J, Gray R. A proportional hazards model for the subdistribution of a competing risk. J Am Statist Assoc 1999: 94: 496–509.
30. Nachega JB, Uthman OA, Anderson J et al. Adherence to antiretroviral therapy during and after pregnancy in low-income, middle-income, and high-income countries: a systematic review and meta-analysis. AIDS 2012: 26: 2039–2052.
31. Wettstein C, Mugglin C, Egger M et al. Missed opportunities to prevent mother-to-child-transmission: systematic review and meta-analysis. AIDS 2012: 26: 2361–2373.
32. Auld AF, Mbofana F, Shiraishi RW et al. Four-year treatment outcomes of adult patients enrolled in Mozambique's rapidly expanding antiretroviral therapy program. PLoS ONE 2011: 6: e18453.
33. Caluwaerts C, Maendaenda R, Maldonado F, Biot M, Ford N, Chu K. Risk factors and true outcomes for lost to follow-up individuals in an antiretroviral treatment programme in Tete, Mozambique. Int Health 2009: 1: 97–101.
34. Kieffer MP, Mattingly M, Giphart A et al. Lessons learned from early implementation of Option B+: the Elizabeth Glaser Pediatric AIDS Foundation experience in 11 African countries. J Acquir Immune Defic Syndr 2014: 67 (Suppl 4): S188–S194.
35. Gourlay A, Birdthistle I, Mburu G, Iorpenda K, Wringe A. Barriers and facilitating factors to the uptake of antiretroviral drugs for prevention of mother-to-child transmission of HIV in sub-Saharan Africa: a systematic review. J Int AIDS Soc 2013;16:18588. doi: 10.7448/IAS.16.1.18588
36. Decroo T, Telfer B, Biot M et al. Distribution of antiretroviral treatment through self-forming groups of patients in Tete Province, Mozambique. J Acquir Immune Defic Syndr 2011: 56: e39–e44.
37. Pestilli S, Llenas-Garcia J, Larsson E, Hobbins M, Ehmer J, Wikman P. Self -help groups of HIV patients may increase retention in care in Northern Mozambique. Kuala Lumpur: 7th IAS, 2013.
38. Decroo T, Koole O, Remartinez D et al. Four-year retention and risk factors for attrition among members of community ART groups in Tete, Mozambique. Trop Med Int Health 2014: 19: 514–521.
39. Micek MA, Gimbel-Sherr K, Baptista AJ et al. Loss to follow-up of adults in public HIV care systems in central Mozambique: identifying obstacles to treatment. J Acquir Immune Defic Syndr 2009;52:397–405.
40. Phillips T, Thebus E, Bekker LG, McIntyre J, Abrams EJ, Myer L. Disengagement of HIV-positive pregnant and postpartum women from antiretroviral therapy services: a cohort study. J Int AIDS Soc 2014; 17: 19242. doi: 10.7448/IAS.17.1.19242. eCollection 2014.
41. Myer L, Abrams EJ, Zhang Y, Duong J, El-Sadr WM, Carter RJ. Family matters: co-enrollment of family members into care is associated with improved outcomes for HIV-infected women initiating antiretroviral therapy. J Acquir Immune Defic Syndr 2014: 67 (Suppl 4): S243–S249.
42. Hodgson I, Plummer ML, Konopka SN et al. A systematic review of individual and contextual factors affecting ART initiation, adherence, and retention for HIV-infected pregnant and postpartum women. PLoS One 2014; 9: e111421. doi: 10.1371/journal.pone.0111421. eCollection 2014.
43. Bemelmans M, Baert S, Goemaere E et al. Community-supported models of care for people on HIV treatment in sub-Saharan Africa. Trop Med Int Health 2014: 19: 968–977.
44. van Lettow M, Bedell R, Mayuni I et al. Towards elimination of mother-to-child transmission of HIV: performance of different models of care for initiating lifelong antiretroviral therapy for pregnant women in Malawi (Option B+). J Int AIDS Soc 2014: 17: 18994.